T-cell Receptor Therapy Market

Key Highlights

• According to the Surveillance, Epidemiology, and End Results Program (SEER), the rate of new cases of ovarian cancer was 10.6 per 100,000 women per year in the US. The death rate was 6.5 per 100,000 women per year. In 2019, there were an estimated 233,565 women living with ovarian cancer in the US.

• T-cell Receptor Therapy epidemiology is segmented as Total incident cases of potential indications (Synovial Sarcoma and Myxoid/Round Cell Liposarcoma, Non-small Cell Lung Cancer, Relapsed or Refractory HPV-16-positive Cancers, Ovarian Cancer, Unresectable or Metastatic Uveal Melanoma and other type of cancer and solid tumors), Total Indication wise eligible cases, and Indication wise treatable cases] in the T-cell Receptor Therapy market report.

Request for unlock CAGR of T-Cell Receptor Therapy Market

DelveInsight's "T-cell Receptor Therapy — Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the T-cell Receptor Therapy, historical and forecasted epidemiology as well as the T-cell Receptor Therapy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The T-cell Receptor Therapy market report provides current treatment practices, emerging drugs, T-cell Receptor Therapy market share of the individual therapies, current and forecasted T-cell Receptor Therapy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current T-cell Receptor Therapy treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019–2032

T-cell Receptor Therapy Market Disease Understanding and Treatment Algorithm

The DelveInsight’s T-cell Receptor Therapy market report gives a thorough understanding of T-cell Receptor Therapy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. T-cell receptor Based adoptive therapy employs genetically modified lymphocytes that are directed against specific tumor markers. This therapeutic modality requires a structured and integrated process that involves patient screening (e.g., for HLA-A*02:01 and specific tumor targets), leukapheresis, generation of transduced T-cell Receptor Therapy product, lymphodepletion, and infusion of the TCR-based adoptive therapy.

Like CAR T-cell therapy, engineered T-cell receptor therapy involves treating cancer with activated T lymphocytes from the body. Both strategies attach new receptors to the cells’ surfaces, enabling them to attack different forms of cancer. The difference between the two methods pertains to what antigens they are capable of recognizing. CAR T cells bind to naturally occurring antigens on the surface of cancer cells. In engineered T-cell Receptor therapy, the added receptors can only link with major histocompatibility complex (MHC) proteins. The manufacturing process for TCR therapy is also virtually the same as the one for CAR T-cell therapy.

The major histocompatibility complex (MHC), is a series of genes responsible for coding antigens that can be recognized by the immune system. The MHC marks foreign pathogens by attaching proteins to their surface for T lymphocytes to bind to. Engineered T-cell Receptor therapy equips activated T cells with specific receptors that target their complementary cancer antigens. This greatly enhances the personalization of treatment and provides a higher potential for positive outcomes for patients.

T-cell Receptor Therapy Epidemiology 

The T-cell Receptor Therapy epidemiology section provides insights about historical and current T-cell Receptor Therapy patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• According to the Surveillance, Epidemiology, and End Results Program (SEER), the rate of new cases of ovarian cancer was 10.6 per 100,000 women per year in the US. The death rate was 6.5 per 100,000 women per year. In 2019, there were an estimated 233,565 women living with ovarian cancer in the US.

• The disease epidemiology covered in the report provides historical as well as forecasted T-cell Receptor Therapy epidemiology [segmented as Total incident cases of potential indications (Synovial Sarcoma and Myxoid/Round Cell Liposarcoma, Non-small Cell Lung Cancer, Relapsed or Refractory HPV-16-positive Cancers, Ovarian Cancer, Unresectable or Metastatic Uveal Melanoma and other type of cancer and solid tumors), Total Indication wise eligible cases, and Indication wise treatable cases] in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan from 2019 to 2032.

Country Wise- T-cell Receptor Therapy Epidemiology

This section provides a glimpse of the T-cell Receptor Therapy epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

T-cell Receptor Therapy Drug Chapters

The drug chapter segment of the T-cell Receptor Therapy report encloses the detailed analysis of T-cell Receptor Therapy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the T-cell Receptor Therapy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

T-cell Receptor Therapy Marketed Drugs

KIMMTRAK (tebentafusp): Immunocore

KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager, approved by the FDA for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) in January 2022.

Note: Detailed Current therapies assessment will be provided in the full report of T-cell Receptor Therapy

T-cell Receptor Therapy Emerging Drugs

GSK3377794 (letetresgene-autoleucel) by GlaxoSmithKline is a T-cell receptor T-cell therapy (TCR-T) which harnesses the immune system to develop a personalized treatment. It does this by extracting a patient’s T-cells, which are then genetically modified to express a T-cell receptor that targets the NY-ESO-1 antigen found in various solid tumors. It received European PRIME and FDA breakthrough status. Additionally GSK is also investigating GSK3901961 (an engineered TCR T-cells, co-expressing the CD8a cell surface receptor, targeting NY-ESO-1) and GSK3845097 (an engineered TCR T-cells, co-expressing the dnTGF-βRII cell surface receptor, targeting NY-ESO-1 mechanism of action).

KITE-439, a therapy based on NCI E7 TCR, was being developed by Kite Pharma, which was later acquired by Gilead Sciences.

MDG1011 is Medigene's first proprietary TCR-T immunotherapy candidate, targeting PRAME. 

Note: Detailed emerging therapies assessment will be provided in the full report of T-cell Receptor Therapy

T-cell Receptor Therapy Market Outlook

Immunotherapies have swiftly risen to become one of the major pillars in cancer treatment. Among them, TCR-engineered T cell therapies are a rapidly growing, active, and evolving field. Due to the remarkable efficacy of CAR T therapies in treating B cell malignancies, interest in CAR T therapy has eclipsed that of TCR T therapy. However, TCR T therapy is gaining interest as CAR T trials have so far failed to elicit satisfactory responses in the treatment of solid cancers. 

TCR-based adoptive cell therapies are currently being tested in a variety of advanced cancers with the results to date indicating that the technology is presumptively safe and prospectively efficacious. Many challenges need to be addressed to fully exploit TCR-based therapies, including those associated with TCR product manufacturing, patient selection, patient preparation with lymphodepletion, administration of treatment and monitoring of adverse events. Overcoming these challenges, and those posed by the immunosuppressive microenvironment, as well as developing next-generation strategies is essential to improving the efficacy and safety of TCR-based therapies.

Engineered TCR therapy encounters the same issues as CAR T-cell therapy when it comes to the difficulties and expenses of separating cells. T cells are not typically available in the necessary numbers to carry out an adequate response to prolonged battles with cancer. When they do become available, they are harnessed for treatment, not research. Medical advancements in the field of adoptive cell therapy are constant but slow due to the inaccessibility of T cells. 

The dynamics of the T-cell Receptor Therapy market is anticipated to change in the coming years owing to the improvement in the research and development undertaking. Key players such as GlaxoSmithKline, Adaptimmune Therapeutics, Gilead Sciences, Immatics, TCR² Therapeutics and various others are involved in developing therapies for T-cell Receptor Therapy.

According to DelveInsight, T-cell Receptor Therapy market in 7MM is expected to witness a major change in the study period 2019-2032.

Analyst Commentary

• The pipeline of T-cell Receptor Therapy is very robust, many potential therapies are being investigated for the treatment of T-cell Receptor Therapy, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the T-cell Receptor Therapy market in the 7MM. Aside from that, the market size of T-cell Receptor Therapy may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

• The market growth of T-cell Receptor Therapy may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

T-cell Receptor Therapy Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the T-cell Receptor Therapy market or expected to get launched in the market during the study period 2019-2032. The analysis covers T-cell Receptor Therapy market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. 

Note: Detailed emerging therapies assessment will be provided in the full report of T-cell Receptor Therapy.

T-cell Receptor Therapy Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes T-cell Receptor Therapy key players involved in developing targeted therapeutics.

T-cell Receptor Therapy Clinical Trial Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for T-cell Receptor Therapy emerging therapies.

Reimbursement Scenario in T-cell Receptor Therapy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the T-cell Receptor Therapy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or T-cell Receptor Therapy market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the T-cell Receptor Therapy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the T-cell Receptor Therapy Market Report

• The report covers the descriptive overview of T-cell Receptor Therapy, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the T-cell Receptor Therapy epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for T-cell Receptor Therapy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the T-cell Receptor Therapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the Global T-cell Receptor Therapy market

T-cell Receptor Therapy Market Report Highlights

• In the coming years, the T-cell Receptor Therapy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence T-cell Receptor Therapy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for T-cell Receptor Therapy. The launch of emerging therapies will significantly impact the T-cell Receptor Therapy market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for T-cell Receptor Therapy
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed T-cell Receptor Therapy clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

T-cell Receptor Therapy Report Insights

• Patient Based Market Forecasting
• Therapeutic Approaches
• T-cell Receptor Therapy Pipeline Analysis
• T-cell Receptor Therapy Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

T-cell Receptor Therapy Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• T-cell Receptor Therapy Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

T-cell Receptor Therapy Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

T-cell Receptor Therapy Market Insights:

• What was the T-cell Receptor Therapy drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the T-cell Receptor Therapy total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest T-cell Receptor Therapy market size during the forecast period (2019-2032)?
• At what CAGR, the T-cell Receptor Therapy market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the T-cell Receptor Therapy market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the T-cell Receptor Therapy market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

T-cell Receptor Therapy Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of T-cell Receptor Therapy?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, France, and Italy) and the UK, and Japan?
• What is the historical T-cell Receptor Therapy patient pool in seven major markets covering the United States, EU4 (Germany, Spain, France, and Italy) and the UK, and Japan?
• What would be the forecasted patient pool of T-cell Receptor Therapy in seven major markets covering the United States, EU4 (Germany, Spain, France, and Italy) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about T-cell Receptor Therapy?
• Out of all 7MM countries, which country would have the highest patient population of T-cell Receptor Therapy during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the T-cell Receptor Therapy treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of T-cell Receptor Therapy in the US, Europe, and Japan?
• What are the T-cell Receptor Therapy marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of T-cell Receptor Therapy?
• How many therapies are in-development by each company for T-cell Receptor Therapy treatment?
• How many are emerging therapies in mid-stage, and late stage of development for T-cell Receptor Therapy treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the T-cell Receptor Therapy therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for T-cell Receptor Therapy and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for T-cell Receptor Therapy?
• What are the global historical and forecasted markets of T-cell Receptor Therapy?

Reasons to buy

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the T-cell Receptor Therapy market
• Organize sales and marketing efforts by identifying the best opportunities for T-cell Receptor Therapy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the T-cell Receptor Therapy market
• To understand the future market competition in the T-cell Receptor Therapy market